Imcheck Therapeutics  will present updated clinical data from the ongoing EVICTION Phase I/IIa trial evaluating ICT01, a first-in-class Butyrophilin (BTN) 3A-targetingmonoclonal antibody, alone and in combination with pembrolizumab in patients with advanced, relapsed/refractory solid and hematological cancers, in one oral presentation and one poster, as well as an additional poster covering preclinical evaluation of ICT01 in combination with a novel IL-2/IL-15 agonist, at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting being held both in person and virtually from November 10 - 14, 2021. 

Details of the oral presentation are:

• Presentation Title: “Clinical Activity of ICT01, an anti-BTN3A-Targeted, γ9δ2-Activating mAb, Alone and in Combination with Pembrolizumab in Patients with Advanced/Refractory Solid Tumors: EVICTION Trial”
• Session Title: Concurrent Rapid Oral Abstract Presentation Session: Clinical
• Abstract Number: 503
• Speaker: Prof. Martin Wermke
• Session Date/Time: November 12, 2021, 12:55 pm - 1:55 pm EST / 18:55 – 19:55 CET

Details of the poster presentations are:

• Poster Title:“Correlation of baseline circulating Vg9Vd2 T cell counts and pharmacodynamic activity of ICT01 in cancer patients: preliminary results from EVICTION and a novel patient enrichment strategy”
• Abstract number: 528
• Session Date/Time: 11/12/2021, 7:00 am - 8:30 pm EST and as ePoster

• Poster Title:“ICT01, an anti-BTN3A monoclonal antibody, and NL-201, an alpha-independent IL-2/IL-15 agonist, combine to elicit a potent anti-tumor response by synergistically stimulating Vg9Vd2 T cell activation and proliferation”
• Abstract number: 563
• Session Date/Time: 11/12/2021 7:00 am – 8:30 pm EST and as ePoster

See the event website https://www.sitcancer.org/2021/home